Trial Information

Summary: KD-247: A New Investigational Anti-HIV Drug

A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, A Humanized Monoclonal Antibody that Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy

This is a double-blind, placebo-controlled, dose escalation study of KD-247 in asymptomatic HIV-1 seropositive subjects who do not currently need antiretroviral therapy. Eligible subjects will be randomized to 1 of 3 cohorts and will receive 3 infusions of 4, 8, or 16 mg/kg of KD-247 or placebo over a 2-week period. A maximum of 9 active subjects and 3 placebo subjects will be allowed per cohort. Study duration is approximately 4 months (including up to 3 weeks between screening and baseline, plus a 12 week follow-up period after the final infusion of study drug).

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:45:53 AM